Quantitation of the monoclonal antibody Denosumab by bioassay and validated LC methods

The monoclonal antibody Denosumab (DmAb) is clinically used to treat osteoporosis and bone loss. We developed a bioassay based on the ability of DmAb to inhibit the effect of human receptor activator of nuclear factor-κB ligand (RANKL) to stimulate the formation of osteoclasts derived from RAW 264.7...

Full description

Saved in:
Bibliographic Details
Published in:International journal of biological macromolecules 2018-11, Vol.119, p.96-104
Main Authors: Perobelli, Rafaela Ferreira, Xavier, Bruna, Silveira, Alice Rosa da, Remuzzi, Gabriel Lunardi, Motta, Luís Gustavo Jung, Dalmora, Sérgio Luiz
Format: Article
Language:English
Subjects:
Animals
Antibodies, Monoclonal - chemistry
Antibodies, Monoclonal - pharmacology
Biological Assay
Chromatography, High Pressure Liquid
Chromatography, Reverse-Phase - methods
Denosumab - chemistry
Denosumab - pharmacology
High-performance liquid chromatography
Mice
Monoclonal antibody Denosumab
RAW 264.7 bioassay
Reproducibility of Results
Sensitivity and Specificity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The monoclonal antibody Denosumab (DmAb) is clinically used to treat osteoporosis and bone loss. We developed a bioassay based on the ability of DmAb to inhibit the effect of human receptor activator of nuclear factor-κB ligand (RANKL) to stimulate the formation of osteoclasts derived from RAW 264.7 cells. This bioassay was applied in conjunction with size exclusion high-performance liquid chromatography (SE–HPLC) and reversed-phase high-performance liquid chromatography (RP–HPLC) methods, with diode array detection (DAD), validated for the quantitation of this biotechnology-derived medicine. The SE–HPLC(DAD) method was carried out on a TSKGel G2000SWXL column and the mobile phase consisted of potassium phosphate buffer with sodium chloride, pH 7.4. The gradient RP–HPLC(DAD) method was carried out on a Vydac 214TP C4 column at 60 °C. The mobile phases consisted of 0.1% v/v trifluoroacetic acid (TFA) in water and 0.1% v/v TFA in acetonitrile. Calibration curves were linear over the concentration ranges 6–200 μg mL−1 and 6–300 μg mL−1 for the SE–HPLC(DAD) and RP–HPLC(DAD) methods respectively. The bioassay results correlated with the LC methods results, indicating the capabilities of these methods to quantitate DmAb, which will contribute to ensure the batch-to-batch consistency and efficacy of this biotherapeutic.
ISSN:0141-8130
1879-0003
DOI:10.1016/j.ijbiomac.2018.07.120